Literature DB >> 1667425

Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure.

H Meyer-Lehnert1, T Bayer, H G Predel, K Glänzer, H J Kramer.   

Abstract

We examined the effects of 60 min alpha-hANP infusion (24 ng/min/kg) on glomerular filtration rate (GFR), renal blood flow (RBF), cardiac index (CI) and blood pressure (BP) in 8 patients with chronic renal failure (CRF) with GFR ranging from 18 to 80 ml/min/1.73 m2 and in 8 control (C) subjects with normal renal function. Basal plasma levels of ANP and cGMP were elevated in CRF (ANP: 60.6 +/- 9.1 vs 13.6 +/- 1.9 pmol/l, p less than 0.05; cGMP: 14.3 +/- 2.9 vs 6.6 +/- 1.1 pmol/ml, p less than 0.05). During ANP infusion, peak levels of cGMP were higher in CRF than in C (27.5 +/- 3.2 vs. 17.3 +/- 1.3 pmol/ml, p less than 0.05). During ANP infusion, GFR increased in CRF by 70.7 +/- 4.2% from 34.5 +/- 6.8 to 57.4 +/- 9.9 ml/min/1.73 m2 (p less than 0.001) as compared to 16.2 +/- 1.4% in C (p less than 0.001 vs CRF). RBF increased in CRF by 43.6 +/- 6.4% and in C by 3.1 +/- 1.2% (p less than 0.01). Basal urinary sodium excretion (UNaV) was slightly lower in CRF than in C but rose to the same level in both groups during ANP infusion. In CRF, as opposed to C, UNaV remained elevated above baseline after the end of the infusion. The effect of ANP on fractional sodium excretion (FENa), however, was more pronounced in C.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1667425     DOI: 10.1007/bf01649565

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  46 in total

1.  Effects of posture and ageing on circulating atrial natriuretic peptide levels in man.

Authors:  B G Haller; H Züst; S Shaw; M P Gnädinger; D E Uehlinger; P Weidmann
Journal:  J Hypertens       Date:  1987-10       Impact factor: 4.844

2.  Low dose infusions of 26- and 28-amino acid human atrial natriuretic peptides in normal man.

Authors:  A M Richards; G Tonolo; P Montorsi; J Finlayson; R Fraser; G Inglis; A Towrie; J J Morton
Journal:  J Clin Endocrinol Metab       Date:  1988-03       Impact factor: 5.958

3.  Plasma levels of atrial natriuretic factor in patients with congestive heart failure.

Authors:  H Nakaoka; K Imataka; M Amano; J Fujii; M Ishibashi; T Yamaji
Journal:  N Engl J Med       Date:  1985-10-03       Impact factor: 91.245

4.  Plasma levels and dialysance of atrial natriuretic peptide in terminal renal failure.

Authors:  H Saxenhofer; M P Gnädinger; P Weidmann; S Shaw; D Schohn; C Hess; D E Uehlinger; H Jahn
Journal:  Kidney Int       Date:  1987-10       Impact factor: 10.612

5.  Atrial natriuretic factor in human blood.

Authors:  T Yamaji; M Ishibashi; F Takaku
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

6.  Release of atriopeptin in the rat by vasoconstrictors or water immersion correlates with changes in right atrial pressure.

Authors:  N Katsube; D Schwartz; P Needleman
Journal:  Biochem Biophys Res Commun       Date:  1985-12-31       Impact factor: 3.575

7.  Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man.

Authors:  T G Yandle; A M Richards; M G Nicholls; R Cuneo; E A Espiner; J H Livesey
Journal:  Life Sci       Date:  1986-05-19       Impact factor: 5.037

8.  Atrial natriuretic factor--a circulating hormone stimulated by volume loading.

Authors:  R E Lang; H Thölken; D Ganten; F C Luft; H Ruskoaho; T Unger
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

9.  Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption.

Authors:  P J Harris; D Thomas; T O Morgan
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

10.  Exaggerated responsiveness of immunoreactive atrial natriuretic peptide to saline infusion in chronic renal failure.

Authors:  R G Walker; C P Swainson; T G Yandle; M G Nicholls; E A Espiner
Journal:  Clin Sci (Lond)       Date:  1987-01       Impact factor: 6.124

View more
  4 in total

1.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2013-08       Impact factor: 2.801

2.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version. JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Jpn J Radiol       Date:  2013-08       Impact factor: 2.374

Review 3.  Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides and neprilysin inhibitors.

Authors:  Juan Brignone; Kasper Bostlund Assersen; Mia Jensen; Boye L Jensen; Brian Kloster; Morten Jønler; Lars Lund
Journal:  Pflugers Arch       Date:  2021-04-12       Impact factor: 3.657

4.  Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.

Authors:  Stefan Willmann; Katrin Coboeken; Stefanie Kapsa; Kirstin Thelen; Markus Mundhenke; Kerstin Fischer; Burkhard Hügl; Wolfgang Mück
Journal:  J Clin Pharmacol       Date:  2021-01-06       Impact factor: 3.126

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.